Universal MI definition update for cardiovascular disease

Current Cardiology Reports

Volumn 16, Issue 6, 2014, Pages

  White, Harvey ^a   Thygesen, Kristian ^b   Alpert, Joseph S ^c   Jaffe, Allan ^d  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Cardiovascular disease; Myocardial infarction; Troponin; Universal definition

Indexed keywords

TROPONIN I; TROPONIN T; BIOLOGICAL MARKER; TROPONIN;

AGE; ANGIOCARDIOGRAPHY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY THROMBOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; ECG ABNORMALITY; GENDER; HEART INFARCTION; HUMAN; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; RESTENOSIS; REVIEW; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SUDDEN DEATH; BLOOD; CLASSIFICATION; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PRACTICE GUIDELINE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PRACTICE GUIDELINES AS TOPIC; TROPONIN;

EID: 84901305360     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-014-0492-5     Document Type: Review

References (64)

1. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC-ACC-AHA-WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-38. (Pubitemid 47616190)
2. •• Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-67. Update of the universal definition on MI with addition of intracoronary thrombus as a criterion, adding new imaging criteria, a new type of MI type 4c and significantly raising the threshold for the diagnosis of type 4a MI.
3. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581-98.
4. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Nat Rev Cardiol. 2012;9:620-33.
5. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020-35.
6. •• White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol. 2011;57:2406-8. Aviewpoint as to whether ischemia without necrosis can cause troponin release from the cell into the blood stream and what are the pathophysiologic causes of troponin elevations. A classification of the 6 possible mechanisms is presented in a table.
7. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48:1-11. (Pubitemid 44202476)
8. Christenson Eric CR. The role of cardiac biomarkers in the diagnosis and management of patients presenting with suspected acute coronary syndrome. Ann Lab Med. 2013;33:309-18.
9. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol. 2013;61:1753-8.
10. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58:54-61.
11. Rosjo H, Andreassen J, Edvardsen T, Omland T. Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardiographic indexes of cardiac function and anatomy. Am J Cardiol. 2011;108:88-91.
12. Ang DS, Kao MP, Dow E, Lang C, Struthers A. The prognostic value of high sensitivity troponin T 7 weeks after an acute coronary syndrome. Heart. 2012;98:1160-5.
13. Rubin J, Matsushita K, Ballantyne CM, Hoogeveen R, Coresh J, Selvin E. Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol. 2012;59:484-9.
14. Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125:1605-16.
15. Turer AT, Addo TA, Martin JL, et al. Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. J Am Coll Cardiol. 2011;57:2398-405.
16. Biener M, Mueller M, Vafaie M, et al. Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. Int J Cardiol. 2013;167:1134-40.
17. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J. 2012;33:2252-7.
18. Hammarsten O, Fu ML, Sigurjonsdottir R, et al. Troponin T percentiles from a random population sample, emergency room patients and patients with myocardial infarction. Clin Chem. 2012;58:628-37.
19. Santalo M, Martin A, Velilla J, et al. Using high-sensitivity troponin T: the importance of the proper gold standard. Am J Med. 2013;126:709-17.
20. Body R, Carley S, McDowell G, et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol. 2011;58:1332-9.
21. Cullen LMC, Parsonage WA, Wildi K, Greenslade JH, Twerenbold R, Aldous S, et al. Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. JACC. 2013;62:1242-9.
22. Bjurman C, Larsson M, Johanson P, et al. Small changes in troponin T levels are common in patients with non-ST-segment elevation myocardial infarction and are linked to higher mortality. J Am Coll Cardiol. 2013;62:1231-8.
23. White HD, Chew DP. Acute myocardial infarction. Lancet. 2008;372:570-84.
24. Bayes de Luna A, Wagner G, Birnbaum Y, et al. A new terminology for left ventricular walls and location of myocardial infarcts that present Q wave based on the standard of cardiac magnetic resonance imaging: a statement for healthcare professionals from a committee appointed by the International Society for Holter and Noninvasive Electrocardiography. Circulation. 2006;114:1755-60. (Pubitemid 44608178)
25. Wong CK, White HD. Patients with circumflex occlusions miss out on reperfusion: how to recognize and manage them. Curr Opin Cardiol. 2012;27:327-30.
26. Matetzky S, Freimark D, Feinberg MS, et al. Acute myocardial infarction with isolated ST-segment elevation in posterior chest leads V7-9: "hidden" ST-segment elevations revealing acute posterior infarction. J Am Coll Cardiol. 1999;34:748-53. (Pubitemid 29436180)
27. Lopez-Sendon J, Coma-Canella I, Alcasena S, Seoane J, Gamallo C. Electrocardiographic findings in acute right ventricular infarction: sensitivity and specificity of electrocardiographic alterations in right precordial leads V4R, V3R, V1, V2, and V3. J Am Coll Cardiol. 1985;6:1273-9. (Pubitemid 16171973)
28. Sgarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. N Engl J Med. 1996;334:481-7. (Pubitemid 26067735)
29. Cai Q, Mehta N, Sgarbossa EB, et al. The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a highrisk population. Are the Sgarbossa Criteria ready for prime time? Am Heart J. 2013;166:409-13.
30. Assomull RG, Lyne JC, Keenan N, et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J. 2007;28:1242-9. (Pubitemid 47343853)
31. Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012;163:768 e2-76 e2.
32. Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction 38: an application of the classification system from the Universal Definition of Myocardial Infarction. Circulation. 2009;119:2758-64.
33. White HD, Reynolds HR, Carvalho AC, et al. Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results fromlong-term follow-up of the Occluded Artery Trial (OAT) cohort. Am Heart J. 2012;163:563-71.
34. Bonaca MP, Wiviott SD, Braunwald E, et al. ACC/AHA/ESC/WHFuniversal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation. 2012;125:577-83.
35. •• Alpert JS, Thygesen KA, White HD, Jaffe AS. Diagnostic and Therapeutic Implications of Type 2 myocardial infarction: review and commentary. Am J Med. 2014;127(2):105-8 Opinion piece using patient cases to illustrate the conundrums in diagnosing and managing type 2 MI.
36. Saaby L, Poulsen TS, Hosbond S, et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med. 2013;126:789-97.
37. Babuin L, Vasile VC, Rio Perez JA, et al. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. Crit Care Med. 2008;36:759-65.
38. Vasile VCBL, Rio-Perez JA, Alegria JR, Song LM, Chai HS, Afessa B, et al. Long term prognostic significance of elevated cardiac troponin levels in critically ill patients with acute gastrointestinal bleeding. Crit Care Med. 2009;37:140-7.
39. Vasile VC, Chai HS, Khambatta S, Afessa B, Jaffe AS. Significance of elevated cardiac troponin T levels in critically ill patients with acute respiratory disease. Am J Med. 2010;123:1049-58.
40. Gualandro DM, Campos CA, Calderaro D, et al. Coronary plaque rupture in patients with myocardial infarction after noncardiac surgery: frequent and dangerous. Atherosclerosis. 2012;222:191-5.
41. Saaby LPT, Hosbond S, Larsen TB, Diederichsen ACP, Schmidt H, Gerke O, et al. Mortality rate in type 2 myocarial infarction: observations from an unselected hospital cohort. Am J Med. 2014. doi:10.1016/j.amjmed.2013.12.020.
42. Tricoci P, Leonardi S, White J, et al. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. J Am Coll Cardiol. 2013;62:242-51.
43. Testa L, Van Gaal WJ, Biondi Zoccai GG, et al. Myocardial infarction after percutaneous coronary intervention: a metaanalysis of troponin elevation applying the new universal definition. QJM. 2009;102:369-78.
44. White HD. The prequel: defining prognostically important criteria in the periprocedural PCI troponin saga. Circ Cardiovasc Interv. 2012;5:142-5.
45. Damman P, Wallentin L, Fox KA, et al. Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR). Circulation. 2012;125:568-76.
46. • Jaffe AS, Apple FS, Lindahl B, Mueller C, Katus HA. Why all the struggle about CK-MB and PCI? Eur Heart J. 2012;33:1046-8. A cogent review of the data in this area with an emphasis on issues related to the use of the appropriate values for the baseline values.
47. Miller WL, Garratt KN, Burritt MF, Lennon RJ, Reeder GS, Jaffe AS. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. Eur Heart J. 2006;27:1061-9.
48. Gustavsson CG, Hansen O, Frennby B. Troponin must be measured before and after PCI to diagnose procedure-related myocardial injury. Scand Cardiovasc J. 2004;38:75-9. (Pubitemid 38659723)
49. Prasad A, Rihal CS, Lennon RJ, SinghM, Jaffe AS, Holmes Jr DR. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv. 2008;1:10-9.
50. Moussa ID, Klein LW, Shah B, et al. Consideration of a new definition of clinically relevantmyocardial infarction after coronary revascularization an expert consensus document from the society for cardiovascular angiography and interventions (SCAI). Catheter Cardiovasc Interv. 2013. doi:10.1002/ccd.25135.
51. Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/ American College of Cardiology consensus recommendations. Clin Chem. 2003;49:1331-6. (Pubitemid 36900619)
52. Apple FS, Jesse RL, Newby LK, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007;53:547-51. (Pubitemid 46580222)
53. Lin JC, Apple FS, Murakami MM, Luepker RV. Rates of positive cardiac troponin I and creatine kinase MB mass among patients hospitalized for suspected acute coronary syndromes. Clin Chem. 2004;50:333-8. (Pubitemid 38156374)
54. Goodman SG, Steg PG, Eagle KA, et al. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2006;151:654-60. (Pubitemid 43290256)
55. Newby LK, Goldmann BU, Ohman EM. Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2003;41:31S-6S. (Pubitemid 36223344)
56. • Costa FM, Ferreira J, Aguiar C, Dores H, Figueira J, Mendes M. Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years. Eur Heart J. 2012;33:2544-50. Study reporting ten year follow-up of patients having had anMI diagnosed by the universal definition with the mortality for these patients being significantly higher than the mortality for patients diagnosed as having an MI by the World Health Organization (WHO) criteria.
57. • Park DW, Kim YH, Yun SC, et al. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention. Eur Heart J. 2013;34:1662-9. A pooled analysis of trials and registries including over 26000 patients reporting that after adjustment for atherosclerotic risk and PCI-related factors elevation of CKMB >5X URL was significantly associated with mortality at 2.9 years.
58. Wang TK, Stewart RA, Ramanathan T, Kang N, Gamble G, White HD. Diagnosis of MI after CABG with high-sensitivity troponin T and new ECG or echocardiogram changes: relationship with mortality and validation of the Universal Definition of MI. Eur Heart J Acute Cardiovasc Care. 2013;2:323-33.
59. Leonardi S, Tricoci P, White HD, et al. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA.CER) trial. Eur Heart J. 2013;34:1723-31.
60. Roger VL, Killian JM, Weston SA, et al. Redefinition of myocardial infarction: prospective evaluation in the community. Circulation. 2006;114:790-7. (Pubitemid 44274920)
61. Salomaa V, Koukkunen H, Ketonen M, et al. A new definition for myocardial infarction: what difference does it make? Eur Heart J. 2005;26:1719-25. (Pubitemid 41222327)
62. White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163:182 e4-90 e4.
63. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303-13.
64. •• Braunwald E, Morrow DA. Unstable angina: is it time for a requiem? Circulation. 2013;127:2452-7. The authors propose a requiem for the term unstable angina as it becomes less and less frequent with the introduction of high sensitivity troponins detecting smaller and smaller amounts of myocardial injury and increasing numbers of patients are diagnosed as having MI.